Q2 2025 · 13F-HR
Affinity Asset Advisors, LLCholdings as filed
Filed 2025-08-13 · accession 0001999371-25-011256
$732.2M
Reported value
91
Positions
2025-06-30
Period end
The Brief · Affinity Asset Advisors, LLC · Q2 2025
AI · grounded in 13F
Affinity Asset Advisors, LLC established a new position in VRNA valued at $57.7M. The fund also initiated new stakes in INSM for $47.8M and XENE for $34.4M. Additional new positions include ACLXGBX at $32.6M and Blueprint Medicines Corp at $32M. The fund ended the period with 88 positions and total AUM of $732.2M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 925050106 | VRNA | VERONA PHARMA PLC | $57.7M | 7.88% | 610,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $47.8M | 6.53% | 475,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $34.4M | 4.70% | 1,100,000 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $32.6M | 4.45% | 495,000 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $32.0M | 4.38% | 250,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $31.7M | 4.32% | 415,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $30.0M | 4.10% | 691,899 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $28.6M | 3.91% | 1,000,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $24.3M | 3.32% | 440,000 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $24.2M | 3.31% | 80,000 | Common | SOLE |
| 881624209 | TEVA | TEVA PHARMACEUTICAL INDS LTD | $23.5M | 3.20% | 1,400,000 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $19.8M | 2.71% | 450,000 | PUT | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $14.4M | 1.97% | 3,589,355 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $14.4M | 1.96% | 970,000 | Common | SOLE |
| G31249108 | ESTA | ESTABLISHMENT LABS HLDGS INC | $14.3M | 1.95% | 334,863 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $13.9M | 1.89% | 2,534,058 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $13.0M | 1.78% | 2,000,308 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $12.8M | 1.75% | 545,000 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $12.2M | 1.66% | 900,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $11.8M | 1.62% | 900,162 | Common | SOLE |
| 48576UAA4 | KPTI 3 10/15/25 | KARYOPHARM THERAPEUTICS INC | $11.6M | 1.59% | 15,250,000 | Common | SOLE |
| 031162100 | AMGN | AMGEN INC | $11.2M | 1.53% | 40,000 | CALL | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $11.0M | 1.51% | 967,620 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $9.8M | 1.34% | 2,200,000 | Common | SOLE |
| H17182108 | CRSP | CRISPR Therapeutics AG | $9.7M | 1.33% | 200,000 | CALL | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $9.7M | 1.33% | 4,536,182 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $9.1M | 1.24% | 606,678 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $8.0M | 1.10% | 400,000 | Common | SOLE |
| N71542109 | PRQR | PROQR THRAPEUTICS N V | $7.1M | 0.98% | 3,499,512 | Common | SOLE |
| 00972D105 | AKBA | AKEBIA THERAPEUTICS INC | $7.1M | 0.97% | 1,950,000 | Common | SOLE |
| 682143AK8 | OMER 9.5 06/15/29 | OMEROS CORP | $7.1M | 0.97% | 9,025,000 | Common | SOLE |
| 45790W108 | — | INOZYME PHARMA INC | $7.0M | 0.96% | 1,749,359 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $6.9M | 0.95% | 3,045,000 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $6.8M | 0.92% | 603,479 | Common | SOLE |
| 89422GAA5 | TVTX 2.25 03/01/29 | TRAVERE THERAPEUTICS INC | $6.7M | 0.91% | 7,000,000 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $6.6M | 0.90% | 150,000 | CALL | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $6.5M | 0.88% | 150,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $5.5M | 0.74% | 390,000 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $5.2M | 0.71% | 50,000 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $5.2M | 0.71% | 4,085,787 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $5.0M | 0.68% | 275,000 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $4.5M | 0.62% | 280,031 | Common | SOLE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $4.5M | 0.62% | 400,000 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $4.4M | 0.60% | 152,252 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $4.1M | 0.56% | 125,000 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAP SOLUTIONS COR | $3.7M | 0.51% | 350,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $3.7M | 0.50% | 70,000 | Common | SOLE |
| 46489V302 | CATX | PERSPECTIVE THERAPEUTICS INC | $3.6M | 0.49% | 1,050,000 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $3.0M | 0.41% | 607,872 | Common | SOLE |
| G6717R120 | OACCU | OAKTREE ACQUISITION CORP III | $2.7M | 0.36% | 250,000 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $2.7M | 0.36% | 25,000 | Common | SOLE |
| 61023L207 | MNPR | MONOPAR THERAPEUTICS INC | $2.4M | 0.33% | 67,500 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $2.3M | 0.31% | 199,643 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $2.1M | 0.29% | 1,500,000 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $2.0M | 0.27% | 370,000 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $2.0M | 0.27% | 263,817 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $2.0M | 0.27% | 245,000 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $1.9M | 0.26% | 135,000 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $1.9M | 0.25% | 1,500,000 | Common | SOLE |
| 14070B309 | CAPR | CAPRICOR THERAPEUTICS INC | $1.7M | 0.24% | 175,000 | PUT | SOLE |
| 03675P102 | AVR | ANTERIS TECHNOLOGIES GLOBAL | $1.6M | 0.22% | 425,000 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $1.6M | 0.22% | 300,000 | Common | SOLE |
| 670002401 | NVAX | NOVAVAX INC | $1.6M | 0.22% | 250,000 | CALL | SOLE |
| N90064101 | QURE | UNIQURE NV | $1.4M | 0.19% | 100,000 | CALL | SOLE |
| 65487U108 | NKTX | NKARTA INC | $1.3M | 0.18% | 800,000 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $1.3M | 0.17% | 24,692 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $1.1M | 0.16% | 500,000 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $1.1M | 0.15% | 250,000 | Common | SOLE |
| 65343E108 | NXTCEUR | NEXTCURE INC | $1.1M | 0.14% | 2,302,598 | Common | SOLE |
| 682143102 | OMER | OMEROS CORP | $942,000 | 0.13% | 314,000 | PUT | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $831,696 | 0.11% | 347,990 | Common | SOLE |
| 45782T105 | INMB | INMUNE BIO INC | $817,740 | 0.11% | 354,000 | PUT | SOLE |
| 02155H200 | ALT | ALTIMMUNE INC | $774,000 | 0.11% | 200,000 | CALL | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $765,000 | 0.10% | 100,000 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $678,825 | 0.09% | 157,500 | CALL | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $652,517 | 0.09% | 65,317 | Common | SOLE |
| 869367102 | STRO | SUTRO BIOPHARMA INC | $537,368 | 0.07% | 752,722 | Common | SOLE |
| 363225202 | GALT | GALECTIN THERAPEUTICS INC | $527,500 | 0.07% | 250,000 | PUT | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $462,000 | 0.06% | 200,000 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $339,410 | 0.05% | 518,025 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $280,280 | 0.04% | 77,000 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $278,000 | 0.04% | 200,000 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $234,502 | 0.03% | 223,335 | Common | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $220,214 | 0.03% | 667,516 | Common | SOLE |
| 75041J101 | RADX | RADIOPHARM THERANOSTICS LTD | $166,059 | 0.02% | 35,635 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $108,575 | 0.01% | 2,500 | PUT | SOLE |
| 00534B100 | ADGM | ADAGIO MED HLDGS INC | $108,000 | 0.01% | 80,000 | Common | SOLE |
| 746964105 | QTTB | Q32 BIO INC | $41,388 | 0.01% | 27,777 | Common | SOLE |
| 03879J100 | ABUS | ARBUTUS BIOPHARMA CORP | $28,737 | 0.00% | 9,300 | CALL | SOLE |
| 77313F114 | RCKTW | ROCKET PHARMACEUTICALS INC | $2,160 | 0.00% | 75,000 | Common | SOLE |
| N44445117 | IMTXW | IMMATICS N.V | $112 | 0.00% | 187,204 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.